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Abstract – Software is becoming an increasingly important aspect of medical devices and medical 
device regulation. Software enables highly complex systems to be built. However, complexity is 
the enemy of safety, therefore strict adherence to well documented processes is important within 
the domain of medical device software. Medical devices can only be marketed if compliance and 
approval from the appropriate regulatory bodies (e.g. the Food and Drug Administration (FDA)) is 
achieved. This paper outlines the development of a software process improvement (SPI) model 
specifically for the medical device industry. The paper details how medical device regulations may 
be satisfied by adopting relevant practices from the Capability Maturity Model Integration 
(1CMMI®). Copyright © 2006 Praise Worthy Prize - All rights reserved. 
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I. Introduction 
Medical device companies base their software 
development processes on the need to comply with the 
FDA [1,2,3,4]. Due to the safety-critical nature of 
medical device software it is important that highly 
efficient software  practices are in place within medical 
device companies. In fact, integrated into the design 
process of medical devices, is the requirement of the 
production and maintenance of a device technical file, 
incorporating a design history file. Design history 
illustrates the well documented, defined and controlled 
processes and outputs, undertaken in the development 
of medical devices and for our particular consideration 
with this framework - the software components. 
The software framework introduced in this paper 
will address an opportunity to integrate regulatory 
issues and process improvement mechanisms in order to 
achieve greater customer satisfaction, faster time to 
market and improved software quality.   
II. The medical device industry 
The risk of patient injury from software defects is a 
concern due to the manufacture and deployment of 
increasing numbers of software-embedded medical 
devices [5],[6],[7]. There have been a number of major 
medical device product recalls over this past 25 years 
that were the result of software defects [8]. Change 
control within medical device software is important as 
such modifications can occur frequently and may occur 
at different levels (e.g. design, interface or code), 
therefore increasing the risk of software failure [8]. It is 
therefore important that a medical device company has 
efficient software development processes in place that 
include change control practices. 
According to the Institute of Medicine report ‘To Err 
is Human’ [9], between 44000 to 98000 people die in 
hospital from preventative medical errors. The report 
also says that more people die every year as a result of 
medical errors than from motor vehicle accidents, breast 
cancer or AIDS. 
Like most industries, the healthcare industry depends 
on computer technology to perform many of the 
functions ranging from financial management to patient 
treatment [10]. The use of software in medical devices 
has become widespread in the last two decades. Medical 
devices with software include those that are supplied 
and used entirely in hospitals and other health facilities, 
as well as consumer items such as blood pressure 
monitors. Many medical devices, and their software, 
operate in real time – monitoring, diagnosing, or 
controlling a physiological process as it changes.  
The complexity and risk profile of medical devices 
varies widely and range from a consumer digital 
thermometer for minor diagnosis, and an implanted 
artificial heart that is critical to preserving a patient’s 
life, to a therapeutic X-ray machine with a computer 
user interface, programmable software controlled 
therapy and anatomical and biophysical modelling in 
the software, which is operated under a high level of 
professional staff supervision [11]. 
Analysis of medical device recalls highlights the 
diverse nature of medical device software failures. The 
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FDA found that approximately 44% of the quality 
problems that led to voluntary recalls of medical 
devices were attributed to errors or deficiencies 
designed into particular medical devices rather than 
having been inserted during the manufacturing phase. 
The study also recognised software quality management 
practices as a means to prevent failure [12]. 
In the medical device industry, the software used to 
control a device takes on an additional role - it must 
help ensure the safety of the user. There are many 
challenges to implementing safe software. Software 
design needs to include deliberate engineering practices 
and rigorous risk analysis and mitigation needs to be 
performed whilst at the same time simultaneously 
addressing potential device failures that may be 
introduced by the software itself [13]. 
III. Background and Contribution  
The main area of concern for medical device 
companies in relation to their software development 
practices is to ensure that the elements  required by the 
Food and Drug Administration (FDA) are in place 
rather than trying to improve their overall software 
development practices. GAMP [14] details practices 
that medical device companies may adopt in order to 
comply with medical device regulations, however no 
standards exist within the medical device domain in 
relation to how such practices could be improved by 
incorporating practices from formal software 
engineering SPI models. Previous research has 
investigated the suitability of using existing software 
quality assurance standards in order to achieve FDA 
compliance related to the areas of process management, 
requirements specification, design control and change 
control [8]. However, no specific software process 
improvement model has been developed for the 
industry.  
However, if we investigate other regulated industries 
such as the automotive and space industries we realise 
that these domains are not content with satisfying 
regulatory standards, but have proactively developed 
SPI models specifically for their domain so that they 
may continuously improve the development of their 
information systems to achieve higher levels of safety, 
greater efficiency, and a faster time to market, whilst 
seamlessly satisfying regulatory quality requirements. 
The major SPI models that currently exist, namely 
ISO/IEC15504 [15] and CMMI® [16], do not address 
the regulatory requirements of either the medical 
device, automotive or space industries. Therefore, a new 
SPI model was developed specifically for the 
automotive industry, this model was based upon 
ISO/IEC15504 and is referred to as Automotive Spice 
[17]. Likewise, a new ISO/IEC15504 based SPI model 
was developed specifically for the space industry, this 
model is known as SPiCE for SPACE [18]. Both of 
these models contain reference and assessment 
information in relation to how companies may improve 
their practices within their domain.  
IV. SPI Framework Development 
Lero (The Irish Software Engineering Research 
Centre) is currently researching how software 
processes my be improved within the embedded 
software industry. As part of this research Lero is 
aiming to develop a software development framework 
for the medical device sector that addresses existing 
regulatory requirements for the control of the design, 
development, maintenance and support of software. 
The approach for delivering the software development 
framework is to establish a model (implemented as 
illustrated in figure 1) that addresses the relevant 
regulations, and integrates those constraints within an 
SPI framework (i.e. Medical Device Software Process 
Improvement-MeDeSPI).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Test in the medical device industry 
 
Figure 1: Software framework approach 
 
 
The model will be flexible in that relevant elements 
of the SPI framework may be adopted as required to 
provide the most significant benefit to the business. 
The intention is develop two frameworks, one that is 
based on ISO:15504 and the other on the CMMI® ).  
For the purpose of this paper, the SPI framework 
used will be that of the CMMI® and the regulations 
used to extend the CMMI® framework will be those of 
the FDA and the ANSI/AAMI SW68:2001 standard 
Extend the CMMI 
with new goals and 
practices 
CMMI 
 
FDA & 
SW68 
 
 
MeDeSPI 
SDMMD:  Software Development 
Method for Medical Devices 
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(SW68) (Medical device software – Software life cycle 
processes) [19]. 
The MeDeSPI framework was initiated by work that 
one of the authors performed whilst performing 
research for the Centre for Software Process 
Technologies at the University of Ulster. This author is 
now progressing this work with Lero. The initial 
research work was assisted by the involvement of a 
steering group with a pilot of 5 medical device 
companies and a notified standards body (all based in 
N.Ireland). However, this research has now been 
extending to include companies throughout Ireland.  
The Software Development Method for Medical 
Devices (SDMMD) will be a defined set of software 
process models (in effect a methodology) which when 
utilised will meet the goals of MeDeSPI. SDMMD will 
cover the complete lifecycle. The project is divided into 
several stages. 
 
1. Assess the need for and commitment to the 
creation of SDMMD and MeDeSPI; 
2. Identify which parts of the CMMI® are 
required to comply with FDA regulation and 
extend the CMMI® with new goals and 
practices that are necessary to achieve FDA 
compliance (i.e. creation of MeDeSPI); 
3. Develop process models for meeting the goals 
of MedeSPI (i.e.create SDMMD); 
4. Test SDMMD with Irish medical device 
companies. 
 
We have completed stage 1 of this work and are 
currently performing  stage 2 activities. In fact stage 2 
has been performed for the risk management [20],  
requirements management [21], and configuration 
management process areas [22].  
V. Process Assessment 
The MeDeSPI model will provide a structured 
approach for appraisal that may be used by 
organisations involved in the development, maintenance 
and support of software with the following purposes: 
 
• Understanding the state of a company’s 
own processes for process improvement; 
• Determining the capability of a company’s 
own processes for a particular contract; 
• Determining the capability of another 
organisation’s processes for a particular 
contract.  
 
Process assessment is an integral part of software 
process improvement and provides a way to measure 
the capability of selected processes in an organisation 
against a target capability profile. Analysis of the 
assessment results enables companies to prioritise 
which processes should be improved in order to 
increase their effectiveness in achieving their business 
goals. The assessment results will also indicate the risks 
involved in undergoing a project using the assessed 
processes. This enables determination of how effective 
they are in achieving their goals, and to identify 
significant causes of poor quality, or overruns in time or 
cost. These provide the criteria to prioritise process 
improvements. 
The process assessment (MeDeSPI) model is 
composed of two main components: 
 
• Process areas; 
• Capability scale.  
 
Section V.1 lists the process areas that are deemed 
applicable to the medical device industry. Section V.2 
details the capability scale against which each process is 
measured. The capability scale is based upon CMMI® 
capability scales. Section V.3 outlines the activities 
performed in an assessment. 
 
V.1.  MeDeSPI Process Areas 
 
SDMMD will provide a software development 
methodology, which addresses the regulatory guidance 
criteria, while introducing best practices that can be 
selected as required.  MeDeSPI will provide a means of 
assessing software engineering capability in eleven 
areas that have been defined by the FDA [1,2,3,4]  as:   
 
1. Level of Concern;  
2. Software Description;  
3. Device Hazard and Risk Analysis;  
4. Software Requirements Specification; 
5. Architecture Design; 
6. Design Specifications; 
7. Requirements Traceability Analysis; 
8. Development; 
9. Validation; 
10. Verification and Testing; 
11. Revision Level History. 
 
MeDeSPI is being developed to promote SPI 
practices into the software development processes of 
medical device companies. This is an attempt to 
improve the effectiveness and efficiency of software 
processes used by medical device companies through 
investigating the mapping between twelve CMMI® 
process areas and the eleven FDA areas listed above. 
The twelve CMMI® process areas that we have deemed 
appropriate for the medical device industry are as 
follows:  
 
1. Project Planning; 
2. Project Monitoring & Control; 
3. Supplier Agreement Management; 
4. Risk Management; 
5. Requirements Management; 
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6. Requirements Development; 
7. Technical Solution; 
8. Product Integration; 
9. Verification; 
10. Validation; 
11. Configuration Management; 
12. Process and Product Quality Assurance. 
 
The mappings between the FDA regulatory 
guidelines and the CMMI® process areas listed above 
then produce twelve MeDeSPI process areas which 
retain the CMMI® process area names listed above. 
Each of the MeDeSPI process areas will then be 
composed of a number of goals and practices. Goals 
and practices may be either generic (relating to the 
entire organisation) or specific (relating to the current 
process area). MeDeSPI investigates what parts of the 
CMMI® process areas are required to satisfy FDA 
regulations, but also investigates the possibility of 
extending the CMMI® process areas with additional 
goals and practices that are outside the remit of 
CMMI®, but are required in order to satisfy FDA 
regulations (see figure 2). 
 
 
 
 
 
 
 
 
 
A- CMMI Practices, not mandatory for  FDA. 
B- CMMI Practices that are required for FDA. 
C- Non-CMMI Practices, mandatory for FDA. 
 
Figure 2. Composition of the MeDeSPI framework. 
 
V.2. MeDeSPI capability  levels 
 
The model will help companies to measure their 
organisational capability and to track progression and 
achievements in each of the twelve process areas and 
against process capability levels. The MeDeSPI 
framework has adopted the following capability levels: 
 
• Level 0 – A particular process is not performed. 
 
• Level Med – Companies must demonstrate that a 
process area satisfies the goals and performs the 
practices required to achieve FDA regulatory 
compliance. This will involve performing some 
practices which the CMMI® views as generic, 
although not to the extent of fulfilling any generic 
goals. 
 
• Level 1 - Companies must demonstrate that a 
process area satisfies level Med and the CMMI® 
capability level 1 goal of performing the CMMI® 
base practices. 
 
• Level 2 – Companies must demonstrate that a 
process area satisfies level 1 and additionally 
performs CMMI® Advanced Practices, as well as 
the CMMI® capability level 2 generic goal of 
Institutionalising a Managed Process. 
 
• Level 3 - Companies must demonstrate that a 
process area satisfies level 2 and additionally the 
CMMI® Generic Goal to Institutionalise a Defined 
Process (CMMI® Generic Goal 3).  
 
•  Level 4 – Companies must demonstrate that a 
process area satisfies level 3 and additionally the 
CMMI® Generic Goal to Institutionalise a 
Quantitatively Managed Process (CMMI® Generic 
Goal 4). 
 
•  Level 5 - Companies must demonstrate that a 
process area satisfies level 4 and additionally the 
CMMI® Generic Goal to Institutionalise an 
Optimising Process (CMMI® Generic Goal 5). 
 
V.3. Assessment method activities 
 
To perform a MeDeSPI assessment the following 
activities will have to be performed: 
 
• Request for process assessment; 
• Planning the assessment schedule; 
• Briefing the company in relation to the 
assessment; 
• Performing the assessment and collecting 
information; 
• Analysing and validating the information 
collected; 
• Providing a rating for the process area; 
• Reporting and inputs to the risk management 
process. 
 
Each process area included in the assessment will be 
appraised on the basis of available evidence. The 
evidence may be gathered using interview, inspecting 
organisational documents or analysing metrics. The 
information collected for each process area will be 
compared against assessment objectives and scope for 
that process area. Information that supports a particular 
process rating will be recorded and maintained as 
A 
B C 
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evidence to substantiate the ratings and to verify 
compliance with the requirements. 
The assessment method activities include a last 
important step “Reporting and providing inputs to the 
risk management process”.  The risk management 
process area is both a process area and the final step of 
the assessment activities, as it is important that risk 
management is assigned a separate process area and that 
issues found in other process areas are also reported into 
the risk management process. This is particularly 
important to software developed or implemented in the 
medical device industry, as it is necessary to implement 
a risk management strategy throughout development. 
The risk management guidelines within the framework 
will acknowledge and endorse the ISO14971:2000 [23] 
standard for “Application of Risk Management to 
Medical Devices”. 
VI. Continuous SPI 
SPI is a continuous process that an organisation 
follows in a cyclic improvement path of performing an 
assessment, implementing the recommendations from 
the assessment to achieve improvement, and then 
starting the cycle again by reassessing to check for 
improvement. Improvement will be achieved by 
following this path and adopting specific improvement 
measures such as the introduction of new or changed 
practices into established processes and removing 
inefficient practices. An important step within the SPI 
cycle is the gathering of information. This information 
is required to establish the current state and 
subsequently to confirm the improvements by 
comparing the initial process assessment results with the 
re-assessment results gathered after the implementation 
of the improvements.  
 
VII. Conclusion 
 
Of particular importance to medical device 
companies is the need to develop medical devices in full 
compliance with the appropriate regulatory bodies that 
govern the sale and marketing of medical devices 
throughout the world. The key business goals of cost 
effective development and speed to market, are 
fundamental factors for all companies, but for small 
new-start companies this is critical. Our studies and 
assessment of the Irish medical device industry 
illustrates that the MeDeSPI model has the potential to 
provide a huge benefit to participating companies as 
business goals and regulatory compliance may both be 
achieved [24]. 
 The MeDeSPI model is still undergoing 
development. We are currently progressing stage 2 of 
the project. Our approach is to examine all of the 
appropriate process areas within the CMMI® and 
ISO/IEC 15504 models that are referred to in the FDA 
regulations, and investigate the extent to which these 
frameworks need to be extended to create MeDeSPI. 
Our vision is to provide a framework that will 
encourage medical device companies to distance 
themselves from the concept of developing the software 
first and then completing the necessary documentation 
that is required to achieve FDA compliance, to instead 
pursuing a continuous SPI path that will produce more 
efficient software development and safer medical 
devices. 
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